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a b s t r a c t
Several studies have reported that short hairpin RNA (shRNA)-mediated RNA interference (RNAi) was
competitively inhibited by the expression of adenovirus (Ad)-encoded small RNAs (VA-RNAs), which are
expressed from a replication-incompetent Ad vector, as well as a wild-type Ad; however, it remained to
be clariﬁed whether an shRNA-expressing Ad vector-mediated knockdown was inhibited by VA-RNAs
transcribed from the same Ad vector genome. In this study, we demonstrated that a lack of VA-RNA
expression from theAdvector leads to an increase in knockdownefﬁciencies of Ad vector-mediatedRNAi.
In the cells transduced with a ﬁrst-generation Ad vector (FG-Ad) expressing shRNA (FG-Ad-shRNA), the
copy numbers of shRNA and VA-RNAs incorporated into the RNA-induced silencing complex (RISC) was
comparable. In contrast, higher amounts of shRNAwere found in the RISCwhen the cellswere transduced
with an shRNA-expressing helper-dependent Ad (HD-Ad) vector, in which all viral genes, including VA-
RNAs, were deleted (HD-Ad-shRNA), compared with FG-Ad-shRNA. HD-Ad vectors expressing shRNA
against luciferase and p53 showed 7.4% and 37.3% increases in the knockdown efﬁciencies compared to
the corresponding FG-Ad-shRNA, respectively, following in vitro transduction. Furthermore, higher levels
of knockdownefﬁciencieswere also foundby the transductionwith shRNA-expressingAd vectors lacking
VA-RNAexpression (AdVR-shRNA) than by transductionwith FG-Ad-shRNA. These results indicate that
VA-RNAs expressed from an Ad vector inhibit knockdown by the shRNA-expressing Ad vector and that
R-shR
201 . HD-Ad-shRNA and AdV
©
. Introduction
RNA interference (RNAi) has become one of the most impor-
ant techniques for both gene-function analysis in basic research
nd silencing of disease-related genes in clinical applications. In
ddition to chemically synthesized small interfering RNA (siRNA),
ectors expressing short hairpin RNA (shRNA) under the control of
NA polymerase III promoters and RNA polymerase II promoters
re widely used to induce RNAi in mammalian cells (Giering et al.,
008; Scherer and Rossi, 2003; Tuschl, 2002). The shRNA-based
ystems for RNAi have various advantages. First, shRNA expres-
ion can be controlled by various types of promoters. Not only the
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ubiquitous U6 and H1 promoters but also tissue-speciﬁc promot-
ers, including the liver-speciﬁc apolipoprotein E enhancer/human
1-antitrypsin promoter, are available for shRNA-mediated knock-
down (Giering et al., 2008). Second, an shRNAexpression cassette is
efﬁciently delivered to targeted cells not only by non-viral vectors,
but also by viral vectors, such as adenovirus (Ad), lentivirus, and
adeno-associated virus vectors. An shRNA-expressing vector canbe
selected, depending on the situation, since each shRNA-expressing
vector has distinct gene-transfer properties and activities (Grimm
and Kay, 2007).
Among the various types of vectors for shRNA expression, Ad
vectors are highly promising as potential shRNA-expressing vec-
tors because of their superior transduction properties (Benihoud
et al., 1999; Koizumi et al., 2007; Xu et al., 2005). We and other
groups previously demonstrated that Ad vector-mediatedRNAi has
great potential for use as an shRNA-expressing vector in a variety of
Open access undller CC BY-NC-ND licenseapplications (Hosono et al., 2005; Hosono et al., 2004; Mizuguchi
et al., 2007; Motegi et al., 2011). However, it was reported that
virus-associated RNA (VA-RNA) I (a major species) and VA-RNA
II (a minor species), which are small RNAs transcribed from the
icense. 
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d genome, inhibit shRNA-mediated RNAi by competition for key
omponents involved in the RNAi pathway (Andersson et al., 2005;
paricio et al., 2006; Lu and Cullen, 2004; Xu et al., 2007). VA-RNA
and II are about 160 nucleotide-long non-coding RNAs encoded
n the Ad genome (bp 10620–10779 and 10876–11038, respec-
ively) (Bhat et al., 1983; Fowlkes and Shenk, 1980;Machitani et al.,
011b; Mathews and Shenk, 1991). After transcription, the VA-
NAs are transported to the cytoplasm by the interaction between
heir terminal stems and exportin-5, and then processed by an
Nase III-type enzyme dicer, resulting in the production of VA-
NA-derived microRNAs (miRNAs) (mivaRNAs) (Andersson et al.,
005; Lu and Cullen, 2004; Xu et al., 2007). After being processed
y the dicer, the mivaRNAs are incorporated into an RNA-induced
ilencing complex (RISC). shRNA is also processed into siRNA
hrough the same pathway. Since VA-RNAs are also expressed
rom a replication-incompetent ﬁrst-generation Ad (FG-Ad) vector
Yamaguchi et al., 2010), VA-RNAs transcribed from FG-Ad vectors
ould inhibit knockdownefﬁciency of FG-Advector-mediatedRNAi
y competitive inhibition of shRNA processing in several steps, i.e.,
ransport by exportin-5, digestion by the dicer, and incorporation
nto RISC. Based on these ﬁndings, we hypothesized that shRNA-
xpressing Ad vectors lacking VA-RNA expression exhibit more
ffective RNAi compared with FG-Ad-shRNA; however, there have
een no studies that directly evaluate the inhibitory effects of VA-
NAs transcribed from the Ad vector genome on shRNA-expressing
d vector (Ad-shRNA)-mediated knockdown.
In the present study, we prepared an shRNA-expressing helper-
ependent Ad (HD-Ad) vector, in which almost all viral coding
equences, includingVA-RNAs (Palmer andNg, 2005),were deleted
HD-Ad-shRNA). Titers of HD-Ad-shRNA and FG-AD-shRNA were
roperly evaluated under the same condition by measuring the
xpression levels of the green ﬂuorescence protein (GFP) gene,
hich was inserted into the Ad vector genome. HD-Ad-shRNA
howed signiﬁcantly higher levels of knockdown efﬁciencies
han FG-Ad-shRNA following in vitro transduction. Furthermore,
hRNA-expressingAd vectors lackingVA-RNAexpression (AdVR-
hRNA), which are designed to lack only VA-RNA-expression
hrough speciﬁc deletion of the transcriptional control elements
f VA-RNA, also showed more efﬁcient knockdown than FG-Ad-
hRNA.
. Materials and methods
.1. Cells
HEK293 (a transformed embryonic kidney cell line), SK HEP-
(a human hepatoma cell line) and VR293 cells (HEK293 cells
nducibly expressing VA-RNA I) were cultured with Dulbecco’s
odiﬁed Eagle’s medium supplemented with 10% fetal bovine
erum (FBS), streptomycin (100g/ml), and penicillin (100U/ml).
I38 (a normal human lung diploid ﬁbroblast) and 116 cells (Cre
ecombinase-expressingcells forpackagingofHD-Advectors)were
ulturedwithMinimumEssentialMedium supplementedwith 10%
BS, streptomycin (100g/ml), and penicillin (100U/ml).
.2. Plasmids and virus
HD-Ad vector plasmids, pSTK129-shLuc-GFP, were constructed
o express shRNA against ﬁreﬂy luciferase as follows. pHM18-GFP,
ontaining a GFP expression cassette driven by a cytomegalovirus
CMV) promoter, was previously constructed using the pEGFP-
1 plasmid (Clontech, Palo Alto, CA) and a shuttle plasmid,
HM18 (Yamaguchi et al., 2010). pHM18-GFP was digested with
baI/SphI, and ligated with the XbaI/SphI fragment of pHM5-ihU6-
u (Mizuguchi et al., 2007) after an SmaI site of pHM5-ihU6-Lurch 178 (2014) 357–363
had been changed into an XbaI site by using XbaI phosphorylated
linkers (New England Biolabs, Beverly, MA), resulting in pHM18-
ihU6-Lu-GFP. pHM18-ihU6-Lu-GFP was digested with NotI, and
the NotI fragments were inserted into the NotI site of pSTK129
(kindly provided by Dr. Ng Philip) (Palmer and Ng, 2003), result-
ing inpSTK129-shLuc-GFP. Then, pSTK129-shLuc-GFPwasdigested
with PmeI, and the liberated viral genomewas transfected into 116
cells expressing Cre recombinase. The HD-Ad vectors were ampli-
ﬁed and puriﬁed as described previously (Palmer and Ng, 2003).
Helper-virus contamination of the HD-Ad vectors was assessed by
quantitative real-timePCR, and the level of contaminationwas esti-
mated to be less than 0.3%. HD-Ad-shp53 was similarly prepared
as described above.
The FG-Ad and AdVR vectors were constructed by means
of an improved in vitro ligation method described previously
(Mizuguchi and Kay, 1998; Mizuguchi and Kay, 1999; Mizuguchi
et al., 2001b; Sakurai et al., 2005) as follows. pHM5 (Mizuguchi
and Kay, 1999) was digested with SphI/KpnI, and ligated with the
SphI/KpnI fragment of pHM18-ihU6-Lu-GFP, resulting in pHM5-
ihU6-Lu-GFP. pHM5-ihU6-Lu-GFPwas digestedwith I-CeuI/PI-SceI,
and then ligated with I-CeuI/PI-SceI-digested pAdHM4 (Mizuguchi
and Kay, 1998) or pAdHM4VR (Machitani et al., 2011a), resulting
in pAdHM4-shLuc-GFP and pAdHM4VR-shLuc-GFP, respectively.
To generate FG-Ad vector particles, pAdHM4-shLuc-GFP was
digested with PacI to release the recombinant viral genome, and
then transfected into HEK293 cells, resulting in FG-Ad-shLuc.
AdVR-shRNA was prepared as previously described using VR293
cells (Machitani et al., 2011a), instead of HEK293 cells. FG-Ad-
shp53was similarly prepared as described above. The ampliﬁed Ad
vectors were puriﬁed by two rounds of cesium chloride-gradient
ultracentrifugation, dialyzed, and stored at −80 ◦C (Mizuguchi
and Kay, 1998). The virus particles (VP) were determined by a
spectrophotometrical method (Mizuguchi et al., 2001a). Biological
titers, which were based on GFP transduction activity, were deter-
mined by serial titration of the vector stocks on SK HEP-1 cells,
followed by ﬂuorescence-activated cell sorter (FACS) analysis for
GFP-positive cells (Machitani et al., 2011a).
2.3. Preparation of SK HEP-1 transformants expressing luciferase
(SK HEP1-Luc)
SK HEP-1 cells were transduced with a lentivirus vector,
LV-RVLuP, expressing the Venus ﬂuorescent protein and ﬁreﬂy
luciferase as a fusion protein linkedwith a 2A-self-cleaving peptide
(see Supplementary Information). The transduced cells expressing
the Venus ﬂuorescent protein were sorted by using a FACSAriaTM
cell sorter (BD Bioscience, San Jose, CA) (Supplemental Fig. 4). The
resulting cells were designated SK HEP-1-Luc cells. SK HEP-1-Luc
cells were cultured with Dulbecco’s modiﬁed Eagle’s medium sup-
plemented with 10% FBS, streptomycin (100g/ml), and penicillin
(100U/ml).
2.4. Determination of small RNA levels incorporated into RISC
RNA incorporated into the RISC was isolated following trans-
duction with Ad vectors using a microRNA Isolation Kit, human
argonaute 2 (Ago2) (Wako, Osaka, Japan) according to the manu-
facturer’s instructions. Brieﬂy, Ago2, which is the main component
of RISC, was immunoprecipitated by anti-Ago2 antibody to recover
RNA in the RISC. After immunoprecipitation, the Ago2-small RNA
complex was eluted using elution solution, and small RNA was
isolated from the complex using Isogen (Nippon Gene, Tokyo,
Japan). Copy numbers of siRNA and VA-RNAs in the isolated RNA
(160ng) were determined by quantitative RT-PCR using Mir-XTM
miRNA ﬁrst-strand synthesis and SYBR® qRT-PCR (Clontech-
Takara, Kyoto, Japan) and primers speciﬁc for the siLuc, sip53, and
Research 178 (2014) 357–363 359
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Fig. 1. Vector plasmids for the generation of FG-Ad-shRNA and HD-Ad-shRNA.
The structure of the vector plasmids (A) pAdHM4-shRNA-GFP (for FG-Ad-shRNA)
and (B) pSTK129-shRNA-GFP (for HD-Ad-shRNA). pA: bovine growth hormone
rM. Machitani et al. / Virus
ivaRNAI. The sequences of the primers were as follows: siLuc,
′-atttcgaagtactcagcgt-3′; sip53, 5′-gtagattaccactggagtc-3′; mivaR-
AI, 5′-gacaacgggggagtgctcc-3′.
.5. Real time RT-PCR analysis
Whole cell lysates for quantitative RT-PCR were prepared from
he cells transduced with Ad vectors using a CellAmp® direct
NA Prep Kit (Takara-Bio, Otsu, Japan). After cell lysis, luciferase
nd p53 mRNA levels were determined by quantitative RT-PCR
sing a One Step SYBR® PrimeScript® RT-PCR Kit II (Takara-Bio,
tsu, Japan). The primers used for quantitative RT-PCR were as
ollows: luciferase-F, 5′-tcctatgattatgtccggttatgtaaa-3′; luciferase-
, 5′-tgtagccatccatccttgtcaa-3′; p53-F, 5′-ccgcagtcagatcctagcg-3′;
53-R, 5′-aatcatccattgcttgggacg-3′.
.6. Luciferase assay
SK HEP-1-Luc cells were transduced with shLuc-expressing Ad
ectors. After a 36-h incubation, luciferase activity in the cells was
etermined using a luciferase assay system (PicaGene LT2.0; Toyo
nki, Tokyo, Japan).
.7. Western blot analysis
Whole-cell extracts were prepared by suspension of the cells
n lysis buffer (20mM HEPES [pH 7.5], 1% Triton X-100, 2mM
GTA, 10% glycerol, 5mM dithiothreitol, 4mM phenylmethyl-
ulfonyl ﬂuoride) 48h after transduction. The protein content
as measured with a protein assay kit (Bio-Rad, Hercules, CA)
sing bovine serum albumin as the standard. Protein samples
15g) were electrophoresed on 12.5% sodium dodecyl sulfate
SDS)–polyacrylamide gels under reducing conditions, followed
y electrotransfer to PVDF membranes (Millipore, Bedford, MA).
fter blocking with 4% skim milk prepared in TBS-T (tween-20,
.1%), themembrane was incubated with anti-p53 antibody (Santa
ruz Biotechnology, Santa Cruz, CA), followed by incubation in the
resence of horseradish peroxidase (HRP)-labeled anti-mouse IgG
ntibody (Cell Signaling Technology, Danvers, MA). Themembrane
as developed with a chemiluminescence kit (ECL Plus Western
lotting detection system; Amersham Biosciences, Piscataway, NJ),
nd then the signals were read with an LAS-3000 imaging system
Fujiﬁlm, Tokyo, Japan).
.8. Statistical analysis
Statistical signiﬁcance was determined using Student’s t-test.
ata are presented as the means± S.D.
. Results
.1. Construction of shRNA-expressing FG-Ad and HD-Ad vectors
First, in order to compare the knockdown efﬁciencies of
G-Ad and HD-Ad vectors expressing shRNA, we constructed
he FG-Ad and HD-Ad vectors carrying a U6 promoter-driven
hRNA-expression cassette to induce knockdown of target genes
luciferase and human p53 genes). In addition, a CMV promoter-
riven GFP-expression cassette was incorporated into the vector
enome topreciselydetermine the titers of theseAdvectors (Fig. 1).
e demonstrated that the transduction efﬁciencies by these Adectors at the same multiplicity of infection (MOI) were compara-
le (Supplemental Figs. 1–3). SK HEP-1 cells weremore susceptible
oAdvector-mediated transduction thanWI38 cells (Supplemental
igs. 1 and 2).(BGH) poly A sequence; ITR: inverted terminal repeat; Amp : ampicillin resistance
gene; HPRT: intron region of human genomic HPRT stuffer sequence; C346: cosmid
C346 human genomic stuffer sequence.
3.2. Copy numbers of siRNA and VA-RNA in the RISC
Next, in order to examinewhether incorporationof siRNAwhich
wasprocessed from the shRNA intoRISCwas inhibitedbyVA-RNAs,
SK HEP-1 cells constitutively expressing ﬁreﬂy luciferase (SK HEP-
1-Luc cells)were transducedwith a FG-Advector expressing shRNA
against the luciferase gene (shLuc) (FG-Ad-shLuc), and then, the
copy numbers of siLuc (the processed form of shLuc) and mivaR-
NAI in the RISCwere determined by real-time RT-PCR. The analysis
demonstrated that the copy numbers of siLuc and mivaRNAI in the
RISC were almost comparable following the transduction with FG-
Ad-shLuc at all theMOIs (Fig. 2A). On the other hand,when the cells
were transduced with an HD-Ad vector expressing shLuc (HD-Ad-
shLuc), a signiﬁcantly higher amount of siLucwas found in the RISC,
compared with FG-Ad-shLuc (Fig. 2B). Transduction with HD-Ad-
shLuc resulted in an approximately 5-fold higher amount of siLuc
in the RISC than that with FG-Ad-shLuc at the MOIs of 1, 3, and
10 (Fig. 2B). A signiﬁcantly higher amount of sip53, which is pro-
cessed from an shRNA against human p53 (shp53), was also found
in the RISC for an HD-Ad vector expressing shp53 (HD-Ad-shp53),
compared with an FG-Ad vector expressing shp53 (FG-Ad-shp53),
in WI38 cells (Fig. 2C). These results suggest that the competition
between shRNA and VA-RNAs, both of which are transcribed from
the same Ad vector genome, in the processing steps leads to the
lower copy numbers of siRNA in the RISC when transduced with
FG-Ad-shRNA, compared with HD-Ad-shRNA.
3.3. Efﬁcient knockdown of target genes by HD-Ad-shRNA
Next, to evaluate the effect of VA-RNAs on the knockdown efﬁ-
ciencies of shRNA-expressing Ad vectors, SK HEP-1-Luc cells were
transduced with FG-Ad-shLuc or HD-Ad-shLuc at an MOI of 1, 3, or
10. In this experiment, we conﬁrmed that a FG-Ad vector express-
ing shRNA against the other gene (p53 gene) (FG-Ad-shp53) did
not knockdown luciferase expression (Supplemental Fig. 4). HD-
Ad-shLucmediated an approximately 10% increase in the efﬁciency
of knockdown of luciferase mRNA at the MOIs of 3 and 10 (Fig. 3A)
360 M. Machitani et al. / Virus Research 178 (2014) 357–363
Fig. 2. Comparison of small RNA levels incorporated into RISC.
(A) Copynumbers of siLuc (the processed formof shLuc) andmivaRNAI in theRNA-induced silencing complex (RISC) recovered fromSKHEP-1-Luc cells following transduction
with FG-Ad-shLuc-GFP. (B) Copy numbers of siLuc andmivaRNAI in the RISC recovered from SKHEP-1-Luc cells following transductionwith HD-Ad-shLuc-GFP. SK HEP-1-Luc
cells were transduced with FG-Ad-shLuc or HD-Ad-shLuc at a multiplicity of infection (MOI) of 1, 3 or 10. Total RNA was recovered from the RNA-induced silencing complex
(RISC) 36h after transductionwith Ad vectors. Copy numbers of siLuc andmivaRNAI were determined by quantitative RT-PCR. The copy number of siLuc in the RISC following
transductionwith FG-Ad-shLuc at anMOI of 1was normalized to 1. (C) Copy numbers of sip53 in the RISC recovered fromWI38 cells following transductionwith FG-Ad-shp53
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nd copy numbers of sip53 were determined by quantitative RT-PCR. The copy num
ormalized to 1. These experiments were repeated at least three times, and represe
nd in the efﬁciency of knockdown of luciferase activity levels at
llMOIs (Fig. 3B), comparedwith FG-Ad-shLuc. Signiﬁcantly higher
nockdown efﬁciencies were also found for HD-Ad-shp53 than
G-Ad-shp53 in WI38 cells (Fig. 4A and B). Surprisingly, the p53-
nockdown efﬁciencies were more greatly improved by the use of
n HD-Ad vector, compared with the luciferase-knockdown efﬁ-
iencies, although the increases in the copy numbers of siLuc in the
ISC were larger than those of sip53 by the use of an HD-Ad vec-
or. A 37% increase in the p53-knockdown efﬁciency was observed
hen the WI38 cells were transduced with HD-Ad-shp53 at an
OI of 100, compared with FG-Ad-shp53 (Fig. 4A). Signiﬁcantly
ore efﬁcient knockdown of p53 was also found for HD-Ad-shp53
han FG-Ad-shp53 in SK HEP-1 (Supplemental Fig. 5). These results
ndicate that HD-Ad-shRNA shows higher levels of knockdown efﬁ-
iencies than FG-Ad-shRNA.
.4. Efﬁcient knockdown of target genes by AdVR-shRNA
As described above, HD-Ad-shRNA showed higher levels of
nockdown efﬁciencies than FG-Ad-shRNA; however, it is unclear
hether the deletion of VA-RNAs really contributed to the
nhanced knockdown efﬁciencies of HD-Ad-shRNA, because HD-
d vectors are devoid of all viral genes, including VA-RNAs (Palmer
nd Ng, 2005). Therefore, in order to further demonstrate that
A-RNAs inhibit shRNA-mediated knockdown, the knockdownOI of 10, 30 or 100. Total RNA was isolated from the RISC 48h after transduction,
f sip53 in the RISC following transduction with FG-Ad-shp53 at an MOI of 10 was
e data are shown. All the data are expressed as means± S.D. (n=3). *p<0.01.
efﬁciencies of shRNA-expressing AdVR vectors were examined
(Fig. 5A). AdVR vectors, which were previously developed by our
group, lack VA-RNA expression due to deletion of the transcrip-
tional control elements for VA-RNA expression (Machitani et al.,
2011a). We conﬁrmed that the transduction efﬁciencies of FG-Ad-
and AdVR-shLuc at the same MOIs were comparable (Supple-
mental Fig. 3). Real-time RT-PCR analysis demonstrated that an
approximately 2-fold higher amount of siLucwas found in the RISC
following transductionwith AdVR-shLuc, comparedwith FG-Ad-
shLuc at anMOI of 10 (Fig. 5B). Furthermore, AdVR-shLuc showed
9.7% higher knockdown efﬁciencies than FG-Ad-shLuc at anMOI of
10 (Fig. 5C and D), suggesting that the deletion of VA-RNAs led to
an enhancement in the knockdown efﬁciency of shRNA-expressing
Ad vectors.
4. Discussion
The aim of this study is to examine whether an shRNA-
expressing Ad vector-mediated knockdown was inhibited by
VA-RNAs transcribed from the same Ad vector genome. So far, pre-
vious studies have reported the suppression of shRNA-mediated
RNAi by VA-RNAs (Andersson et al., 2005; Lu and Cullen, 2004);
however, shRNA and VA-RNAs were expressed separately from
the two different plasmids in these studies. In this study, we con-
structed shRNA-expressing HD-Ad vectors and AdVR vectors,
M. Machitani et al. / Virus Research 178 (2014) 357–363 361
Fig. 3. Knockdown efﬁciencies of FG-Ad-shLuc and HD-Ad-shLuc in SK HEP-1-Luc
cells.
Luciferase mRNA levels (A) and luciferase activity (B) following transduction with
FG-Ad-shLuc or HD-Ad-shLuc in SK HEP-1-Luc cells. SK HEP-1-Luc cells were trans-
duced with FG-Ad-shLuc or HD-Ad-shLuc at a multiplicity of infection (MOI) of 1,
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Fig. 4. Knockdown efﬁciencies of FG-Ad-shp53 and HD-Ad-shp53 in WI38 cells.
(A) p53 mRNA levels following transduction with FG-Ad-shLuc or HD-Ad-shLuc in
WI38 cells. Cells were transduced with FG-Ad-shp53 or HD-Ad-shp53 at an MOI of
10, 30 or 100. After a 48-h incubation,mRNA levels of the p53 genewere determined
by quantitative RT-PCR. All the data are expressed as themeans± S.D. (n=4). (B) p53
protein levels following transduction with FG-Ad-shLuc or HD-Ad-shLuc in WI38
cells. WI38 cells were transduced with FG-Ad-shp53 or HD-Ad-shp53 at an MOI of
10, 30 or 100. After a 48-h incubation,Western blot analysis for p53was performed.or 10. After a 36-h incubation, mRNA levels of the luciferase gene and luciferase
ctivity were determined. *p<0.05, **p<0.01.
hich do not express VA-RNAs, and evaluated the knockdown
fﬁciencies. shRNA-expressing HD-Ad vectors and AdVR vectors
xhibited higher knockdown efﬁciencies than shRNA-expressing
G-Ad vectors in this study. VA-RNAs and miRNA/shRNA shares
he common processing steps, including export into cytosol, diges-
ion by dicer, and loading into RISC. Lu et al. demonstrated that
A-RNAs competitively inhibit miRNA biogenesis (Lu and Cullen,
004). In addition, VA-RNAs have recently been demonstrated to
uppress dicer expression by competitive binding for exportin-5
etween dicer mRNA (Bennasser et al., 2011). Therefore, HD-Ad-
nd AdVR-shRNA do not inhibit miRNA processing due to the
ack of VA-RNA expression. This property is highly crucial, espe-
ially for shRNA-expressing Ad vectors. Grimm et al. reported that
verexpression of shRNA in the liver resulted in suppression of
iRNA processing, leading to severe hepatotoxicity (Grimm et al.,
006). ExpressionofbothVA-RNAsandshRNAmight inhibitmiRNA
rocessing more severely than shRNA alone.
The present study suggests that HD-Ad-shRNA and AdVR-
hRNA have greater potential to efﬁciently induce RNAi effects,
ompared with FG-Ad-shRNA. The application of HD-Ad- and
dVR-shRNAwill behelpful fordecreasing theviral dose required
o achieve an RNAi-mediated therapeutic effect. Furthermore, HD-These experiments were repeated at least three times, and representative data are
shown. *p<0.05, **p<0.01.
Ad-shRNA eliminates the possibility of leaky expression of the viral
gene and subsequent toxic effects, because HD-Ad vectors delete
almost all of the viral coding sequence. These characteristics could
contribute to a reduction of the immunological side effects caused
by the Ad vector itself (Chen et al., 2003; Jooss and Chirmule, 2003;
Koizumi et al., 2007; Liu andMuruve, 2003;Muruve, 2004; Sakurai
et al., 2008; Xu et al., 2005; Yamaguchi et al., 2007).
As described above, HD-Ad and AdVR vectors are superior
to FG-Ad vectors in the shRNA-mediated knockdown efﬁciencies;
however, the expression of VA-RNAs from the plasmids resulted
in higher levels of reduction in the shRNA-mediated knockdown
efﬁciencies, compared with the differences in the knockdown efﬁ-
ciencies between FG-Ad vectors and HD-Ad vectors or AdVR
vectors shown in the present study. Andersson et al. reported
that knockdown efﬁciencies by plasmids expressing shLuc were
attenuated from about 80% to 30% by co-transfection with plas-
mids expressing VA-RNAs (Andersson et al., 2005). Similar results
were shown by Lu et al. (Lu and Cullen, 2004) This is probably
because the expression levels of VA-RNAs per plasmid-transfected
cellwere higher than those per Ad vector-transduced cell, although
the numbers of VA-RNA-expressing cells were lower for the plas-
mid transfection than for transduction with an Ad vector.
Therewasnoapparent correlationbetween theknockdownefﬁ-
ciencies of shRNA-expressing Ad vectors and the copy numbers of
the siRNA in the RISC. About 5-fold higher amounts of siLuc were
found in the RISC following transduction with HD-Ad-shLuc, com-
pared with FG-Ad-shLuc; however, HD-Ad-shLuc showed only a
7.4% increase in the knockdown efﬁciencies compared with FG-
Ad-shLuc (Fig. 3A and B). Although AdVR-shLuc mediated about
2-fold elevation in the copy number of siLuc in the RISC at MOI of
362 M. Machitani et al. / Virus Research 178 (2014) 357–363
Fig. 5. Knockdown efﬁciencies of FG-Ad-shLuc and AdVR-shLuc.
(A) The structure of the vector plasmid, pAdVR-shLuc-GFP. pA: bovine growth hormone (BGH) pA sequence; ITR: inverted terminal repeat; Ampr: ampicillin resistance gene.
(B) Copy numbers of siLuc in the RISC recovered from SK HEP-1-Luc cells following transduction with FG-Ad-shLuc or AdVR-shLuc. SK HEP-1-Luc cells were transduced
with FG-Ad-shLuc or AdVR-shLuc at amultiplicity of infection (MOI) of 1, 3 or 10. After a 36-h incubation, total RNAwas extracted from the RISC. The copy numbers of siLuc
were determined by quantitative RT-PCR. The copy number of siLuc in the RNA-induced silencing complex (RISC) following transduction with FG-Ad-shLuc at an MOI of 1
was normalized to 1. The data are expressed as the means± S.D. (n=3). (C, D) Luciferase mRNA levels (C) and luciferase activity (D) following transduction with FG-Ad-shLuc
o d-shL
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sr AdVR-shLuc. SK HEP-1-Luc cells were transduced with FG-Ad-shLuc or HD-A
ene and luciferase production were determined. These experiments were repeate
eans± S.D. (n=4). *p<0.05, **p<0.01.
0, comparedwith FG-Ad-shLuc, approximately 10% increase in the
nockdown efﬁciency was found for AdVR-shLuc. On the other
and, HD-Ad-shp53 showed a 37.3% increase in the knockdown
fﬁciencies in WI38 cells, compared with FG-Ad-shp53 (Fig. 4A),
lthough there was an approximately 2-fold increase in the copy
umber of sip53 following transduction with HD-Ad-shp53, com-
ared with FG-Ad-shp53 (Fig. 2C). It might be difﬁcult to largely
mprove the knockdown efﬁciency of shLuc used in this study by
eletion of VA-RNA gene from the Ad vector genome because suf-
ciently efﬁcient knockdown of luciferase gene was obtained even
y FG-Ad-shLuc. By contrast, knockdown of p53 by FG-Ad-shp53
as less efﬁcient than that of luciferase by FG-Ad-shLuc. Therefore,
eletion of VA-RNA gene more largely elevated the knockdown
fﬁciencies of shp53. A previous study demonstrated that over-
xpression of Ago2 more dramatically improved the knockdown
fﬁciency of less efﬁcient siRNA thanhighpotent siRNA (Diederichs
t al., 2008). The degree of increase in the knockdown efﬁciencies
f HD-Ad-shRNA would be different depending on target genes,
ransduced cells, and/or knockdown capacity of shRNA.
. ConclusionsIn summary, we have demonstrated that VA-RNAs expressed
rom the Ad vector genome inhibited efﬁcient knockdown by Ad
ector-mediated RNAi. To the best of our knowledge, this is the ﬁrst
tudy demonstrating the effects of Ad vector-derived VA-RNAs onuc at an MOI of 1, 3 or 10. After a 36-h incubation, mRNA levels of the luciferase
ast three times, and representative data are shown. The data are expressed as the
Ad vector-mediated RNAi. HD-Ad and AdVR vectors are highly
promising as a platform for shRNA-mediated knockdown and to
provide important clues for the improvement of RNAi-mediated
knockdown systems using Ad vectors.
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